Name | Pamidronate Disodium |
Description | Pamidronate Disodium (CGP 23339A), a nitrogen-containing bisphosphonate, can help to strengthen bones. |
In vitro | In ovariectomized rats, Pamidronate significantly enhanced bone density and trabecular weight. Additionally, in rats treated with Growth Hormone (GH), Pamidronate reduced the levels of IGF-I. |
In vivo | In human osteoblast-like cells, Pamidronate (1 μM) enhances the level of OPG mRNA and protein secretion in a dose-dependent manner. Additionally, in mouse osteoclast-like cells (IC50=0.58 μM), Pamidronate inhibits the resorption of calcium phosphate films. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : Insoluble H2O : 10 mM, Sonication is recommended.
|
Keywords | Pamidronate Disodium | Pamidronate | HAP | FPPS |
Inhibitors Related | Doxorubicin hydrochloride | Osthole | RO8191 | Cetylpyridinium Chloride | Tenofovir Disoproxil Fumarate | Thiamine hydrochloride | 4,5-Dicaffeoylquinic acid | 4-Hydroxyacetophenone | Telbivudine | Tenofovir | Osalmid | Bifendate |
Related Compound Libraries | Bioactive Compound Library | Pediatric Drug Library | ReFRAME Related Library | Drug-induced Liver Injury (DILI) Compound Library | Anti-Cancer Clinical Compound Library | Anti-Viral Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |